Evidence map›Paper›PMID 36002454›Full record

ArticleNPJ biofilms and microbiomes2022

Temporal dynamics of oropharyngeal microbiome among SARS-CoV-2 patients reveals continued dysbiosis even after Viral Clearance.

Suman Kalyan Paine, Usha Kiran Rout, Chandrika Bhattacharyya, Debaprasad Parai, Mahabub Alam, Rasmi Ranjan Nanda, Devashish Tripathi, Parveena Choudhury, Chanakya Nath Kundu, Sanghamitra Pati and 2 more

Open access · goldAbstract read
In one paragraph

Article in NPJ biofilms and microbiomes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Microbiome and Long COVID-19: Current Evidence and Insights.International journal of molecular sciences · 2025
    Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Suman Kalyan Paine *National Institute of Biomedical Genomics, Kalyani, 741251, West Bengal, India.
Usha Kiran Rout *ICMR-Regional Medical Research Centre (Dept. of Health Research, Ministry of Health & Family Welfare, Govt. of India), Chandrasekharpur, Bhubaneswar, 751023, Odisha, India.
Chandrika Bhattacharyya *National Institute of Biomedical Genomics, Kalyani, 741251, West Bengal, India.
Debaprasad ParaiICMR-Regional Medical Research Centre (Dept. of Health Research, Ministry of Health & Family Welfare, Govt. of India), Chandrasekharpur, Bhubaneswar, 751023, Odisha, India.
Mahabub AlamNational Institute of Biomedical Genomics, Kalyani, 741251, West Bengal, India.
Rasmi Ranjan NandaICMR-Regional Medical Research Centre (Dept. of Health Research, Ministry of Health & Family Welfare, Govt. of India), Chandrasekharpur, Bhubaneswar, 751023, Odisha, India.
Devashish TripathiNational Institute of Biomedical Genomics, Kalyani, 741251, West Bengal, India.
Parveena ChoudhuryNational Institute of Biomedical Genomics, Kalyani, 741251, West Bengal, India.
Chanakya Nath KunduKIIT School of Biotechnology, Campus XI, Patia, Bhubaneswar, 751024, Odisha, India.
Sanghamitra PatiICMR-Regional Medical Research Centre (Dept. of Health Research, Ministry of Health & Family Welfare, Govt. of India), Chandrasekharpur, Bhubaneswar, 751023, Odisha, India.
Debdutta BhattacharyaICMR-Regional Medical Research Centre (Dept. of Health Research, Ministry of Health & Family Welfare, Govt. of India), Chandrasekharpur, Bhubaneswar, 751023, Odisha, India. drdebdutta.bhattacharya@yahoo.co.in.
Analabha BasuNational Institute of Biomedical Genomics, Kalyani, 741251, West Bengal, India. ab1@nibmg.ac.in.ORCID 0000-0002-1564-0284
National Institute of Biomedical Genomics · INRegional Medical Research Centre · INKIIT University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has posed multiple challenges to global public health. Clinical features and sequela of SARS-CoV-2 infection include long-term and short-term complications often clinically indistinguishable from bacterial sepsis and acute lung infection. Post-hoc studies of previous SARS outbreaks postulate secondary bacterial infections with microbial dysbiosis. Oral microbial dysbiosis, particularly the altered proportion of Firmicutes and Proteobacteria, observed in other respiratory virus infection, like influenza, has shown to be associated with increased morbidity and mortality. Oropharynx and lung share similar kinds of bacterial species. We hypothesized that alteration in the Human Oropharyngeal Microbiome in SARS-CoV-2 patients can be a clinical indicator of bacterial infection related complications. We made a longitudinal comparison of oropharyngeal microbiome of 20 SARS-CoV-2 patients over a period of 30 days; at three time points, with a 15 days interval; contrasting them with a matched group of 10 healthy controls. Present observation indicates that posterior segment of the oropharyngeal microbiome is a key reservoir for bacteria causing pneumonia and chronic lung infection on SARS-CoV-2 infection. Oropharyngeal microbiome is indeed altered and its α-diversity decreases, indicating reduced stability, in all SARS-CoV-2 positive individuals right at Day-1; i.e. within ~24 h of post clinical diagnosis. The dysbiosis persists long-term (30 days) irrespective of viral clearance and/or administration of antibiotics. There is a severe depletion of commensal bacteria phyla like Firmicutes among the patients and that depletion is compensated by higher proportion of bacteria associated with sepsis and severe lung infection from phyla Proteobacteria. We also found elevated proportions of certain genus that have previously been shown to be causal for lung pneumonia in studies of model organisms and human autopsies' including Stenotrophomonas, Acenetobactor, Enterobactor, Klebsiella and Chryseobacterium that were to be elevated among the cases. We also show that responses to the antibiotics (Azithromycin and Doxycycline) are not uniform for all individuals.

Indexed as

CoinfectionCOVID-19MicrobiotaPneumonia, BacterialSepsisAnti-Bacterial AgentsBacteriaDysbiosisHumansOropharynxSARS-CoV-2Anti-Bacterial Agents

Identifiers

PMID36002454
PMCPMC9400563
OpenAlexW4293103902

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.